Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 77.2% from a year ago
Cash & equivalents stood at $40.18M at the end of Q1 FY2026, up 77.2% from a year earlier and up 9.4% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.
Context
- Cash & equivalents amounted to 55.9% of total assets at the end of Q1 FY2026, up 7.1 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +77.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 36.72M USD
- Year-over-year change
- +37.9%
- 4-year CAGR
- +14.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.72M | +37.9% |
| FY2024 | 2024-12-31 | 26.63M | +100.7% |
| FY2023 | 2023-12-31 | 13.27M | -44.2% |
| FY2022 | 2022-12-31 | 23.77M | +12.7% |
| FY2021 | 2021-12-31 | 21.1M | — |
Cash & Equivalents vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's Mar 2026 cash & equivalents of $40.18M is the 4th highest of the 11 companies compared; the peer median is $29.22M.
- Its year-over-year change of +77.2% is the 3rd highest of 11, against a peer median of -44.0%.
- Cash & equivalents amounts to 55.9% of total assets for FENC, versus a peer median of 23.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $118.64M | -34.2% | +5.5% | 41.1% | |
| Mar 2026 | $62.44M | +135.6% | +44.6% | 63.3% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $58.69M | +113.8% | +48.2% | 40.2% |
| Mar 2026 | $40.18M | +77.2% | +15.6% | 55.9% | |
| Mar 2026 | $34.93M | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $30.07M | -69.4% | -15.1% | 22.6% | |
| Mar 2026 | $28.37M | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $24.99M | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $21.76M | -46.0% | +4.8% | 18.2% | |
| Mar 2026 | $14.63M | -56.0% | -52.4% | 8.2% | |
| Mar 2026 | $12.06M | -59.0% | -40.4% | 8.1% | |
| Peer median (excluding FENC) | $29.22M | -44.0% | +5.2% | 23.8% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.1M | 23.77M | 13.27M | 26.63M | 36.72M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 1.55M | 8.81M | 12.88M | 23.18M |
| Inventory | 0 | 576K | 2.16M | 1.06M | 1.56M |
| Other Current Assets | 253K | 63K | 44K | 466K | 1.37M |
| Total Current Assets | 22.39M | 26.73M | 26.86M | 44.12M | 66.56M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.79M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 27K | 211K | 6K | 822K | 710.62K |
| Total Non-current Assets | 27K | 211K | 6K | 822K | 3.5M |
| Total Assets | 22.41M | 26.94M | 26.86M | 44.95M | 70.07M |
| Account Payables | 777K | 2.39M | 3.78M | 3.24M | 4.63M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 247.55K |
| Other Current Liabilities | 0 | 0 | 0 | 248K | (10.25K) |
| Total Current Liabilities | 1.65M | 4.61M | 7.55M | 6.92M | 10.5M |
| Long-term Debt | 4.99M | 24.9M | 30.93M | 19.34M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 24.56M |
| Other Non-current Liabilities | 0 | 0 | 0 | 24.56M | 0 |
| Total Non-current Liabilities | 4.99M | 24.9M | 30.93M | 43.9M | 24.52M |
| Total Liabilities | 6.64M | 29.51M | 38.49M | 50.82M | 35.02M |
| Common Stock | 140.8M | 142.59M | 144.31M | 145.61M | 189.56M |
| Retained Earnings | (179.49M) | (203.2M) | (219.25M) | (219.68M) | (229.36M) |
| Accumulated OCI | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Other Stockholders Equity | 0 | 25.75K | 0 | 1 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.77M | (2.57M) | (11.62M) | (5.87M) | 35.05M |
| Total Debt | 4.99M | 24.9M | 30.95M | 19.34M | 0 |
| Net Debt | (16.11M) | 1.13M | 17.69M | (7.29M) | (36.72M) |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.